LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

Search

Thermo Fisher Scientific Inc

Geschlossen

BrancheGesundheitswesen

464.25 -1.7

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

456.16

Max

473.35

Schlüsselkennzahlen

By Trading Economics

Einkommen

-314M

1.7B

Verkäufe

-1.2B

11B

KGV

Branchendurchschnitt

25.772

49.8

EPS

5.44

Dividendenrendite

0.38

Gewinnspanne

15.048

Angestellte

125,000

EBITDA

-905M

2.3B

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+30.74% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

0.38%

2.25%

Nächstes Ergebnis

22. Juli 2026

Nächste Dividendenausschüttung

14. Juli 2026

Nächstes Ex-Dividendendatum

12. Juni 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-24B

172B

Vorheriger Eröffnungskurs

465.95

Vorheriger Schlusskurs

464.25

Nachrichtenstimmung

By Acuity

44%

56%

165 / 347 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Bearish Evidence

Thermo Fisher Scientific Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

23. Apr. 2026, 13:56 UTC

Ergebnisse

Thermo Fisher Profit Up, Warns of Inflation from Iran War -- Update

23. Apr. 2026, 10:28 UTC

Ergebnisse

Thermo Fisher Posts Higher 1Q Profit, Revenue

29. Jan. 2026, 11:34 UTC

Ergebnisse

Thermo Fisher 4Q Profit Rises as Biopharma Spending Rebounds

29. Okt. 2025, 10:51 UTC

Akquisitionen, Fusionen, Übernahmen

Thermo Fisher Scientific Agrees to Buy Clario Holdings for $8.88 billion

23. Okt. 2025, 20:49 UTC

Ergebnisse

Correction to Thermo Fisher Article on Oct. 22

22. Okt. 2025, 10:28 UTC

Ergebnisse

Thermo Fisher 3Q Revenue Rises, Boosted by Life Sciences Business

23. Apr. 2026, 10:01 UTC

Ergebnisse

Thermo Fisher 1Q Organic Revenue Rose 1% >TMO

23. Apr. 2026, 10:01 UTC

Ergebnisse

Thermo Fisher: Well Positioned to Deliver Strong Year >TMO

23. Apr. 2026, 10:00 UTC

Ergebnisse

Thermo Fisher 1Q Net $1.65B >TMO

23. Apr. 2026, 10:00 UTC

Ergebnisse

Thermo Fisher 1Q Adj EPS $5.44 >TMO

23. Apr. 2026, 10:00 UTC

Ergebnisse

Thermo Fisher 1Q EPS $4.43 >TMO

23. Apr. 2026, 10:00 UTC

Ergebnisse

Thermo Fisher 1Q Rev $11.01B >TMO

24. März 2026, 12:04 UTC

Akquisitionen, Fusionen, Übernahmen

Thermo Fisher Completes Acquisition of Clario Holdings for $8.875 Billion >TMO

24. März 2026, 12:00 UTC

Akquisitionen, Fusionen, Übernahmen

Thermo Fisher Scientific Completes Acquisition Of Clario Holdings, Inc. >TMO

29. Jan. 2026, 11:01 UTC

Ergebnisse

Thermo Fisher 4Q Organic Revenue Rose 3% >TMO

29. Jan. 2026, 11:00 UTC

Ergebnisse

Thermo Fisher: Entering 2026 From Position of Strength >TMO

29. Jan. 2026, 11:00 UTC

Ergebnisse

Thermo Fisher 4Q Net $1.96B >TMO

29. Jan. 2026, 11:00 UTC

Ergebnisse

Thermo Fisher 4Q Rev $12.22B >TMO

29. Jan. 2026, 11:00 UTC

Ergebnisse

Thermo Fisher 4Q EPS $5.21 >TMO

29. Jan. 2026, 11:00 UTC

Ergebnisse

Thermo Fisher 4Q Adj EPS $6.57 >TMO

29. Okt. 2025, 10:06 UTC

Akquisitionen, Fusionen, Übernahmen

Thermo Fisher: Clario Provides Endpoint Data Solutions for Clinical Trials >TMO

29. Okt. 2025, 10:05 UTC

Akquisitionen, Fusionen, Übernahmen

Thermo Fisher: Claro Deal Includes Potential Additional Earnout, Other Payments >TMO

29. Okt. 2025, 10:05 UTC

Akquisitionen, Fusionen, Übernahmen

Thermo Fisher to Buy Clario From Group Led by Astorg and Nordic Cap, Novo Holding, Cinven >TMO

29. Okt. 2025, 10:04 UTC

Akquisitionen, Fusionen, Übernahmen

Thermo Fisher Scientific to Pay $8.875 Billion at Closing for Clario Holdings >TMO

29. Okt. 2025, 10:00 UTC

Akquisitionen, Fusionen, Übernahmen

Thermo Fisher Scientific to Acquire Clario Holdings >TMO

22. Okt. 2025, 10:01 UTC

Ergebnisse

Thermo Fisher 3Q Organic Revenue Rose 3% >TMO

22. Okt. 2025, 10:00 UTC

Ergebnisse

Thermo Fisher: In Great Position to Deliver on 2025 Objectives >TMO

22. Okt. 2025, 10:00 UTC

Ergebnisse

Thermo Fisher 3Q Adj EPS $5.79 >TMO

22. Okt. 2025, 10:00 UTC

Ergebnisse

Thermo Fisher 3Q Rev $11.12B >TMO

22. Okt. 2025, 10:00 UTC

Ergebnisse

Thermo Fisher 3Q Net $1.62B >TMO

Peer-Vergleich

Kursveränderung

Thermo Fisher Scientific Inc Prognose

Kursziel

By TipRanks

30.74% Vorteil

12-Monats-Prognose

Durchschnitt 620.29 USD  30.74%

Hoch 685 USD

Tief 560 USD

Basierend auf 16 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Thermo Fisher Scientific Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

16 ratings

15

Buy

1

Halten

0

Sell

Technischer Score

By Trading Central

406.5 / 417.79Unterstützung & Widerstand

Kurzfristig

Bearish Evidence

Mittelfristig

Bearish Evidence

Langfristig

Strong Bearish Evidence

Stimmung

By Acuity

165 / 347 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Überdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Thermo Fisher Scientific Inc

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, protein detection assays, and instruments; immunodiagnostics develops, manufactures and markets complete bloodtest systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. It offers products and services through a direct sales force, customer-service professionals, electronic commerce, and third-party distributors under Thermo Scientific; Applied Biosystems; Invitrogen; Fisher Scientific; Unity Lab Services; and Patheon and PPD. It has a collaboration agreement with Mainz Biomed N.V. for the development of colorectal cancer screening product. Thermo Fisher Scientific Inc. was founded in 1956 and is headquar
help-icon Live chat